JP7899159B2 - 抗血小板薬およびその使用 - Google Patents

抗血小板薬およびその使用

Info

Publication number
JP7899159B2
JP7899159B2 JP2023506150A JP2023506150A JP7899159B2 JP 7899159 B2 JP7899159 B2 JP 7899159B2 JP 2023506150 A JP2023506150 A JP 2023506150A JP 2023506150 A JP2023506150 A JP 2023506150A JP 7899159 B2 JP7899159 B2 JP 7899159B2
Authority
JP
Japan
Prior art keywords
mmol
approximately
compounds
saturated
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023506150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535815A5 (cg-RX-API-DMAC7.html
JP2023535815A (ja
Inventor
グ,ジ-キアン
ザン,ユアンチャオ
ヘ,ゴンシン
ホウ,カイ
ウ,ハオ
Original Assignee
シャンハイ キュアジーン ファーマシューティカル カンパニー,リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ キュアジーン ファーマシューティカル カンパニー,リミテッド filed Critical シャンハイ キュアジーン ファーマシューティカル カンパニー,リミテッド
Publication of JP2023535815A publication Critical patent/JP2023535815A/ja
Publication of JP2023535815A5 publication Critical patent/JP2023535815A5/ja
Application granted granted Critical
Publication of JP7899159B2 publication Critical patent/JP7899159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP2023506150A 2020-07-29 2021-07-28 抗血小板薬およびその使用 Active JP7899159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof

Publications (3)

Publication Number Publication Date
JP2023535815A JP2023535815A (ja) 2023-08-21
JP2023535815A5 JP2023535815A5 (cg-RX-API-DMAC7.html) 2024-08-13
JP7899159B2 true JP7899159B2 (ja) 2026-08-03

Family

ID=80037185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506150A Active JP7899159B2 (ja) 2020-07-29 2021-07-28 抗血小板薬およびその使用

Country Status (14)

Country Link
US (2) US12410132B2 (cg-RX-API-DMAC7.html)
EP (2) EP4342532B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906376B1 (cg-RX-API-DMAC7.html)
CN (4) CN119552111B (cg-RX-API-DMAC7.html)
AR (1) AR123078A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021317436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3046366T3 (cg-RX-API-DMAC7.html)
IL (1) IL299979A (cg-RX-API-DMAC7.html)
MX (1) MX2023001232A (cg-RX-API-DMAC7.html)
TW (1) TWI925859B (cg-RX-API-DMAC7.html)
WO (1) WO2022022559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532B (zh) * 2023-06-29 2026-05-15 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554368A (zh) 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106554368A (zh) 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BLUET, Guillaume et al.,"Synthesis of the stabilized active metabolite of clopidogrel",Tetrahedron,2014年,Vol. 70,No. 25,p. 3893-3900,DOI: 10.1016/j.tet.2014.04.037
DANSETTE, Patrick M. et al.,"Metabolic Activation of Prasugrel: Nature of the Two Competitive Pathways Resulting in the Opening of Its Thiophene Ring",Chemical Research in Toxicology,2012年,Vol. 25,No. 5,p. 1058-1065,DOI: 10.1021/tx3000279
DELAVENNE, Xavier et al.,"Ultra‐performance LC MS/MS method for quantification of clopidogrel active metabolite",Journal of Separation Science,2010年,Vol. 33,No. 13,p. 1968-1972,DOI: 10.1002/jssc.201000115
FARID, Nagy A. et al.,"Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry",Rapid Communications in Mass Spectrometry,2007年,Vol. 21,No. 2,p. 169-179,DOI: 10.1002/rcm.2813
FURLONG, Michael T. et al.,"A validated HPLCMS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study",Journal of Chromatography B,2013年,Vol. 926,p. 36-41,DOI: 10.1016/j.jchromb.2013.02.031
HAGIHARA, Katsunobu et al.,"Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate",Drug Metabolism and Disposition,Vol. 40,No. 9,2012年,p. 1854-1859,DOI: 10.1124/dmd.112.045914
LIU, Cai et al.,"Development and validation of a sensitive and rapid UHPLCMS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma",Journal of Pharmaceutical and Biomedical Analysis,2018年,Vol. 149,p. 394-402,DOI: 10.1016/j.jpba.2017.11.019
Liu, Shuai-bing et al.,Determination of clopidogrel and its metabolites in plasma by UPLC-MS/MS and application in pharmacokinetic study,Yaowu Fenxi Zazhi,2015年,Vol. 35,No. 1,p. 56-63
SHAW, Scott A. et al.,"Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development",The Journal of Organic Chemistry,2015年,Vol. 80,No. 14,p. 7019-7032,DOI: 10.1021/acs.joc.5b00632
TAKAHASHI, Makoto et al.,"Quantitative determination of clopidogrel active metabolite in human plasma by LCMS/MS",Journal of Pharmaceutical and Biomedical Analysis,2008年,Vol. 48,No. 4,p. 1219-1224,DOI: 10.1016/j.jpba.2008.08.020
Tian, Xi et al.,Determination of clopidogrel and its active metabolite in human plasma by LC-MS/MS,Zhongguo Yiyao Gongye Zazhi,2016年,Vol. 47,No. 2,p. 202-206,DOI: 10.16522/j.cnki.cjph.2016.02.016
内田哲郎ら,(5-Methyl-2-oxo-1,3-dioxol-4-yl) methyl Thiamine Sulfideの合成と性状,薬学雑誌,2006年,Vol. 126,No. 3,p. 179-186,DOI: 10.1248/yakushi.126.179

Also Published As

Publication number Publication date
CN116194459A (zh) 2023-05-30
KR20230047425A (ko) 2023-04-07
IL299979A (en) 2023-03-01
TW202214609A (zh) 2022-04-16
CN119033782A (zh) 2024-11-29
TWI925859B (zh) 2026-05-21
KR20250073569A (ko) 2025-05-27
MX2023001232A (es) 2023-05-15
US20250333382A1 (en) 2025-10-30
EP4342532C0 (en) 2025-09-03
US20240279178A1 (en) 2024-08-22
AU2021317436A1 (en) 2023-02-23
ES3046366T3 (en) 2025-12-01
CN119552111A (zh) 2025-03-04
CA3186645A1 (en) 2022-02-03
EP4342532B1 (en) 2025-09-03
CN119552111B (zh) 2026-01-02
EP4188935A1 (en) 2023-06-07
KR102906376B1 (ko) 2025-12-30
AR123078A1 (es) 2022-10-26
WO2022022559A1 (en) 2022-02-03
CN119033782B (zh) 2025-04-25
US12410132B2 (en) 2025-09-09
EP4342532A3 (en) 2024-07-17
EP4188935A4 (en) 2024-07-17
EP4342532A2 (en) 2024-03-27
BR112023001595A2 (pt) 2023-04-04
CN117343000A (zh) 2024-01-05
JP2023535815A (ja) 2023-08-21

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250612

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260722

R150 Certificate of patent or registration of utility model

Ref document number: 7899159

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150